Literature DB >> 25064316

Surgical management of pancreatic neoplasms: what's new?

Andreas Karachristos1, Nestor F Esnaola.   

Abstract

Pancreatic cancer is the fourth leading cause of cancer deaths in the USA. Although some patients will present with premalignant pancreatic lesions (i.e., intraductal papillary mucinous neoplasms) or localized tumors amenable to curative resection, the majority of patients will unfortunately present with technically unresectable or metastatic disease. This review of the recent medical literature will discuss the optimal work-up and management of premalignant pancreatic lesions and the surgical management of localized, borderline resectable, and locally advanced (i.e., unresectable) pancreatic tumors. It will focus on new criteria used to define surgical "resectability," the significance and clinical impact of surgical margins, the role of multimodality therapy in the management of patients with borderline resectable or locally advanced tumors, the role of surgery for local or distant recurrence, and minimally invasive surgical approaches.

Entities:  

Mesh:

Year:  2014        PMID: 25064316     DOI: 10.1007/s11894-014-0397-x

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  30 in total

1.  The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Seiko Hirono; Masaji Tani; Manabu Kawai; Ken-ichi Okada; Motoki Miyazawa; Atsushi Shimizu; Yuji Kitahata; Hiroki Yamaue
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

2.  Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

Authors:  Katia T Papalezova; Douglas S Tyler; Dan G Blazer; Bryan M Clary; Brian G Czito; Herbert I Hurwitz; Hope E Uronis; Theodore N Pappas; Christopher G Willett; Rebekah R White
Journal:  J Surg Oncol       Date:  2012-02-06       Impact factor: 3.454

Review 3.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

4.  Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic adenocarcinoma following neoadjuvant therapy.

Authors:  Joel M Baumgartner; Alyssa Krasinskas; Mustapha Daouadi; Amer Zureikat; Wallis Marsh; Kenneth Lee; David Bartlett; A James Moser; Herbert J Zeh
Journal:  J Gastrointest Surg       Date:  2012-03-08       Impact factor: 3.452

5.  Defining quality for distal pancreatectomy: does the laparoscopic approach protect patients from poor quality outcomes?

Authors:  Marshall S Baker; Karen L Sherman; Susan Stocker; Amanda V Hayman; David J Bentrem; Richard A Prinz; Mark S Talamonti
Journal:  J Gastrointest Surg       Date:  2012-12-06       Impact factor: 3.452

6.  Tumor-positive resection margins reflect an aggressive tumor biology in pancreatic cancer.

Authors:  Charles W Kimbrough; Charles R St Hill; Robert C G Martin; Kelly M McMasters; Charles R Scoggins
Journal:  J Surg Oncol       Date:  2013-02-28       Impact factor: 3.454

7.  Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results.

Authors:  J G Fortner
Journal:  Ann Surg       Date:  1984-04       Impact factor: 12.969

8.  Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

Authors:  Ioannis T Konstantinidis; Andrew L Warshaw; Jill N Allen; Lawrence S Blaszkowsky; Carlos Fernandez-Del Castillo; Vikram Deshpande; Theodore S Hong; Eunice L Kwak; Gregory Y Lauwers; David P Ryan; Jennifer A Wargo; Keith D Lillemoe; Cristina R Ferrone
Journal:  Ann Surg       Date:  2013-04       Impact factor: 12.969

9.  Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm?

Authors:  Jin He; John L Cameron; Nita Ahuja; Martin A Makary; Kenzo Hirose; Michael A Choti; Richard D Schulick; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang
Journal:  J Am Coll Surg       Date:  2013-02-06       Impact factor: 6.113

10.  Small (Sendai negative) branch-duct IPMNs: not harmless.

Authors:  Stefan Fritz; Miriam Klauss; Frank Bergmann; Thilo Hackert; Werner Hartwig; Oliver Strobel; Bogata D Bundy; Markus W Büchler; Jens Werner
Journal:  Ann Surg       Date:  2012-08       Impact factor: 12.969

View more
  4 in total

Review 1.  Pancreatic cystic neoplasms: Review of current knowledge, diagnostic challenges, and management options.

Authors:  Tanima Jana; Jennifer Shroff; Manoop S Bhutani
Journal:  J Carcinog       Date:  2015-03-14

2.  Pancreatic cancer stromal biology and therapy.

Authors:  Dacheng Xie; Keping Xie
Journal:  Genes Dis       Date:  2015-06-01

3.  Impact of postoperative glycemic control and nutritional status on clinical outcomes after total pancreatectomy.

Authors:  Hao-Jun Shi; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2017-01-14       Impact factor: 5.742

Review 4.  Exosomes and the Future of Immunotherapy in Pancreatic Cancer.

Authors:  Ines A Batista; Sonia A Melo
Journal:  Int J Mol Sci       Date:  2019-01-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.